Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) EBT Margin (2016 - 2025)

Vanda Pharmaceuticals' EBT Margin history spans 16 years, with the latest figure at 66.42% for Q4 2025.

  • On a quarterly basis, EBT Margin fell 5420.0% to 66.42% in Q4 2025 year-over-year; TTM through Dec 2025 was 64.16%, a 5263.0% decrease, with the full-year FY2025 number at 64.16%, down 5263.0% from a year prior.
  • EBT Margin hit 66.42% in Q4 2025 for Vanda Pharmaceuticals, down from 50.46% in the prior quarter.
  • Over the last five years, EBT Margin for VNDA hit a ceiling of 18.56% in Q2 2021 and a floor of 74.67% in Q1 2025.
  • Historically, EBT Margin has averaged 10.69% across 5 years, with a median of 1.99% in 2023.
  • Biggest five-year swings in EBT Margin: surged 2141bps in 2023 and later crashed -6485bps in 2025.
  • Tracing VNDA's EBT Margin over 5 years: stood at 12.66% in 2021, then increased by 18bps to 14.91% in 2022, then plummeted by -125bps to 3.67% in 2023, then tumbled by -233bps to 12.22% in 2024, then crashed by -444bps to 66.42% in 2025.
  • Business Quant data shows EBT Margin for VNDA at 66.42% in Q4 2025, 50.46% in Q3 2025, and 66.34% in Q2 2025.